Logo Lanfrica
  • Home
  • Atlas
  • Insights
  • Docs
  • Sign in

© 2026 Lanfrica. All rights reserved. All copyrights of the resources shown on the Lanfrica website belong to the original copyright holders, unless explicitly stated otherwise.

Geographical Scope of Randomized Clinical Trials From Africa

Domain:

healthcare

Record type:

paper
Creator:
AmeOde
Publisher:
Und
Host:avatar
Objective Africa ranks second of the 7 continents in population and geographical area. Reports of research from Africa are often labeled as being African in scope, a dubious claim given the low likelihood of analyzing data representative of 1.4 billion people. Accurate reporting of the scope of research studies in Africa avoids mischaracterization and bias that could have significant implications on health care resource distribution, research funding, and policy making. This study characterized the geographical scope of reports of randomized clinical trials (RCTs) conducted in Africa, because RCTs are most likely to inform clinical practice and policy. Design A tailored PubMed search was developed using Medical Subject Headings and keywords to represent Africa, African, and RCTs. Citations from January 1, 1968, to February 25, 2022, were included. Titles and abstracts were reviewed against established inclusion and exclusion criteria followed by a full-text review of included citations and data extraction. Based on the number of countries, studies were categorized as national (1 country), binational (2 countries), trinational (3 countries), multinational (≥4 countries), and continentwide (multinational, inclusive of all 5 subregions: North, Southern, Central, East, and West). Results A total of 285 RCTs met inclusion criteria, and only 1 was continentwide. Of the 54 African countries, 14 (25%) were not represented in the published RCTs. The top 3 countries were in East Africa, namely, Kenya (80), Uganda (79), and Tanzania (56). Studies were reported as African (201 [71%]), sub-Saharan African (45 [16%]), West African (16 [6%]), East African (14 [5%]), Southern African (7 [2%]), and East + Central or West + Central African (2 [<1%]). The median number of countries included by reported scope was 2 (IQR, 1-3) overall, and similar in African and sub-Saharan African studies; 3.5 (IQR, 2-4) in East African studies; 1 (IQR, 1-2) in West African studies; and 2 (IQR, 2-2) in Southern African studies. A total of 124 studies (44%) were national, 66 (23%) were binational, 33 (11%) were trinational, and 62 (22%) were multinational. Of 201 studies reported as African, 91 (45%) were national, 49 (25%) were binational, 21 (10%) were trinational, 39 (19%) were multinational, and 1 (<1%) was continentwide. Among the 45 (16%) sub-Saharan African studies, 20 (45%) were national, 6 (13%) were binational, 9 (20%) were trinational, and 10 (22%) were multinational. Among the 14 (5%) East African studies, 2 (14%) were national, 3 (22%) were binational, 2 (14%) were trinational, and 7 (50%) were multinational. Of the 16 studies (6%) conducted in West Africa, 10 (62%) were national, 3 (19%) were binational, and 3 (19%) were multinational. Among the 7 RCTs from Southern Africa, 1 (14%) was national, 5 (72%) were binational, and 1 (14%) was trinational. Conclusions The scope of RCTs from Africa is rarely continentwide, and 1 in 4 countries is not included. Conflict of Interest Disclosures None reported. assets.underline.io

Visit

doi.orgunderline.io

Tags

Peer ReviewOperation Management

Similar

Geographical scope of DNO analysis.Cancer Clinical Trials AfricaLandscape of Oncology Clinical Trials in AfricaSWOT Analysis of Oncology Clinical Trials in Africa: A Town Hall Report From the Global Congress on Oncology Clinical Trials in BlacksExperience and challenges from clinical trials with malaria vaccines in AfricaNo-flip ShangRing circumcision in 10-12 year old boys: Results from randomized clinical trials in Kenya

Geographical scope of DNO analysis.

Antimicrobial resistance (AMR) is a major global public health concern, particularly in low-

Cancer Clinical Trials Africa

⚠️ Synthetic dataset — Parameterized from published SSA literature, not real observations. Not suita

Landscape of Oncology Clinical Trials in Africa

PURPOSE The burden of cancer in Africa is of significant concern for several reasons, including th

SWOT Analysis of Oncology Clinical Trials in Africa: A Town Hall Report From the Global Congress on Oncology Clinical Trials in Blacks

Cancer is rapidly becoming a public health crisis as a result of the continued growth and ageing of

Experience and challenges from clinical trials with malaria vaccines in Africa

No-flip ShangRing circumcision in 10-12 year old boys: Results from randomized clinical trials in Kenya